Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nonmyeloablative Allogeneic PBPC Transplant for Severe Congenital Anemias
NCT02038478Phase 2Withdrawn
- Sponsor
- UT Southwestern Medical Center
- Start
- Jan 2014
- Primary completion
- Jan 2021
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in sickle cell disease (SCD) and thalassemia, sponsored by UT Southwestern Medical Center. Primary endpoint: Treatment Success at One Year at 1 year. Planned start Jan 2014; status: withdrawn.
02
Conditions
sickle cell disease (SCD)thalassemia
Beyond the preview
Go deeper on NCT02038478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02038478.